Oral albuterol pharmacokinetics
Pro Research Analysisby 
Searched over 200M research papers
Oral Albuterol Pharmacokinetics: Absorption, Distribution, and Elimination
Oral albuterol is rapidly absorbed, with peak plasma concentrations typically reached within 1.8 to 2.0 hours after administration of standard tablet or syrup formulations in healthy volunteers. The drug’s absorption follows first-order kinetics and is best described by a two-compartment open model, indicating both a rapid distribution phase and a slower elimination phase Powell1986Powell1985.
The elimination half-life of oral albuterol ranges from approximately 4.8 to 6.5 hours, and steady-state plasma levels are generally achieved by the third day of regular dosing (every six hours) Powell1986Powell1985. After multiple doses, a small accumulation is observed, with accumulation ratios around two based on area under the curve (AUC) and peak/trough concentrations .
Bioavailability and Formulation Comparisons
The bioavailability of albuterol from oral tablets is equivalent to that from oral solutions or syrups, regardless of differences in inactive excipients . Controlled-release and sustained-release formulations of albuterol have been shown to be bioequivalent to conventional formulations, with similar AUC and peak concentrations, but they provide a more sustained release and lower peak-to-trough fluctuations Xiao1995Hussey1991Jian2000. Extended-release products like Volmax and Proventil Repetabs show similar overall exposure, but Volmax produces less fluctuation between peak and trough levels, indicating a more controlled release profile .
Effect of Food on Oral Albuterol Pharmacokinetics
Food intake reduces the peak plasma concentration (Cmax) of extended-release albuterol formulations by about 19–21% and delays the time to reach peak concentration (Tmax), but it does not affect the overall extent of absorption (AUC). This suggests that food causes a more gradual and sustained release of albuterol from these formulations, without reducing the total amount absorbed .
Enantiomer-Specific Pharmacokinetics
Albuterol is administered as a racemic mixture, but only one enantiomer (the eutomer) is pharmacologically active. The bioavailability of the active eutomer is lower than that of the inactive distomer, likely due to more efficient metabolism when administered alone. The active enantiomer is more potent in its pharmacodynamic effects, but its plasma exposure is lower compared to when given as part of the racemate .
Influence of Gender, Race, and Genetics
Gender differences affect the apparent volume of distribution of oral albuterol, with men having a higher volume and thus lower peak concentrations compared to women. However, when adjusted for ideal body weight, these differences disappear. Race does not significantly affect albuterol pharmacokinetics, except for minor differences in lag time .
Genetic polymorphisms in the β2-adrenergic receptor gene significantly influence the bronchodilator response to albuterol, with certain genotypes (Arg16 homozygotes) showing a greater and more rapid increase in lung function compared to others (Gly16 carriers) .
Conclusion
Oral albuterol is rapidly absorbed and eliminated, with predictable pharmacokinetics across different formulations and dosing regimens. Extended- and sustained-release formulations provide more stable plasma concentrations, and food can further smooth out peak levels without reducing total absorption. The pharmacokinetics are generally consistent across populations, though gender, body composition, and genetic factors can influence drug distribution and response. The active enantiomer of albuterol is more potent but less bioavailable due to faster metabolism. Overall, oral albuterol pharmacokinetics are well-characterized, supporting its safe and effective use in clinical practice.
Sources and full results
Most relevant research papers on this topic